BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32982177)

  • 1. Synthesis and Bioactivity of
    Cui AL; Sun WF; Zhong ZJ; Jin J; Xue ST; Wu S; Li YH; Li ZR
    Drug Des Devel Ther; 2020; 14():3723-3729. PubMed ID: 32982177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compound IMB-Z inhibits hepatitis B virus replication through increasing APOBEC3G expression and incorporation into viral nucleocapsids.
    Hu J; Wang H; Yang L; Wu S; Li Y; Li Y; Li Z
    J Glob Antimicrob Resist; 2022 Dec; 31():371-378. PubMed ID: 36396043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents.
    Liu Y; Peng Y; Lu J; Wang J; Ma H; Song C; Liu B; Qiao Y; Yu W; Wu J; Chang J
    Eur J Med Chem; 2018 Jan; 143():137-149. PubMed ID: 29174810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
    Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
    J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity.
    Wang H; Zhong M; Li Y; Li K; Wu S; Guo T; Cen S; Jiang J; Li Z; Li Y
    Antiviral Res; 2019 May; 165():23-33. PubMed ID: 30862444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-hepatitis B virus activities of α-DDB-FNC, a novel nucleoside-biphenyldicarboxylate compound in cells and ducks, and its anti-immunological liver injury effect in mice.
    Yang Q; Zhao X; Zang L; Fang X; Zhao J; Yang X; Wang Q; Zheng L; Chang J
    Antiviral Res; 2012 Dec; 96(3):333-9. PubMed ID: 23098744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.
    Yang L; Shi LP; Chen HJ; Tong XK; Wang GF; Zhang YM; Wang WL; Feng CL; He PL; Zhu FH; Hao YH; Wang BJ; Yang DL; Tang W; Nan FJ; Zuo JP
    Acta Pharmacol Sin; 2014 Mar; 35(3):410-8. PubMed ID: 24487969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents.
    Gu X; Zhang Y; Zou Y; Li X; Guan M; Zhou Q; Qiu J
    Bioorg Med Chem; 2021 Jan; 29():115892. PubMed ID: 33285406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo anti-hepatitis B virus activities of the lignan nirtetralin B isolated from Phyllanthus niruri L.
    Liu S; Wei W; Li Y; Lin X; Shi K; Cao X; Zhou M
    J Ethnopharmacol; 2014 Nov; 157():62-8. PubMed ID: 25260580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-hepatitis B virus activity of wogonin in vitro and in vivo.
    Guo Q; Zhao L; You Q; Yang Y; Gu H; Song G; Lu N; Xin J
    Antiviral Res; 2007 Apr; 74(1):16-24. PubMed ID: 17280723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
    Qiu J; Gong Q; Gao J; Chen W; Zhang Y; Gu X; Tang D
    Eur J Med Chem; 2018 Jan; 144():424-434. PubMed ID: 29288943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from Phyllanthus niruri L.
    Liu S; Wei W; Shi K; Cao X; Zhou M; Liu Z
    J Ethnopharmacol; 2014 Sep; 155(2):1061-7. PubMed ID: 25009077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.
    Srivastav NC; Shakya N; Mak M; Agrawal B; Tyrrell DL; Kumar R
    J Med Chem; 2010 Oct; 53(19):7156-66. PubMed ID: 20857959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.
    Campagna MR; Liu F; Mao R; Mills C; Cai D; Guo F; Zhao X; Ye H; Cuconati A; Guo H; Chang J; Xu X; Block TM; Guo JT
    J Virol; 2013 Jun; 87(12):6931-42. PubMed ID: 23576513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
    Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
    Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and anti-HBV activity of NVR3-778 derivatives.
    Lv K; Wu S; Li W; Geng Y; Wu M; Zhou J; Li Y; Gao Q; Liu M
    Bioorg Chem; 2020 Jan; 94():103363. PubMed ID: 31669092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
    Geng CA; Huang XY; Ma YB; Zhang XM; Chen JJ
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1568-71. PubMed ID: 25737009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization and Synthesis of Pyridazinone Derivatives as Novel Inhibitors of Hepatitis B Virus by Inducing Genome-free Capsid Formation.
    Lu D; Liu F; Xing W; Tong X; Wang L; Wang Y; Zeng L; Feng C; Yang L; Zuo J; Hu Y
    ACS Infect Dis; 2017 Mar; 3(3):199-205. PubMed ID: 27989113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.